Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIq-ai Ltd Share News (IQAI)

Share Price Information for Iq-ai Ltd (IQAI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.60
Bid: 1.50
Ask: 1.70
Change: 0.10 (6.67%)
Spread: 0.20 (13.333%)
Open: 1.50
High: 1.625
Low: 1.50
Prev. Close: 1.50
IQAI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK TRADING UPDATE SUMMARY: Primorus Sells Remaining Greatland Stake

Wed, 04th Nov 2020 20:19

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

----------

Primorus Investments PLC - investment firm focused on natural resources sector - Says it has completed the sales of its remaining shareholding in Greatland Gold PLC. Primorus sold 20.0 million shares at an average price of 23.09 pence each, raising gross proceeds of around GBP4.6 million through a "structured series" of sales. As a result, the company no longer holds an interest in Greatland. "The Greatland Gold investment has, by any measure, been extremely successful. Having made a high-conviction investment call in late 2018, it has been hugely satisfying to watch Greatland grow to a market cap in excess of GBP800 million. Whilst the outlook for Greatland is extremely positive, after nearly 2 years, it is time for Primorus to realise its remaining gains and look to re-invest elsewhere in accordance with its investment mandate. Current cash reserves of Primorus now exceed the market capitalisation of the company," says Alastair Clayton, executive director of Primorus.

----------

IQ-AI Ltd - medical software company with headquarters in Jersey - Says the US Food & Drug Administration has granted 510(k) market clearance for the Liver Surface Nodularity software application. IQ-AI's subsidiary, Imaging Biometrics LLC, entered into a business agreement with the owner of LSN, AI Metrics LLC, earlier this year which granted IB global rights to manufacture, market, and distribute the LSN software platform. "Now that the FDA has granted market clearance, IB and AI Metrics will begin to actively market and sell LSN in the USA. CE mark for European distribution and commercialisation is expected later this quarter," says IQ-AI.

----------

GSTechnologies Ltd - data infrastructure, storage, and technology services firm - Wholly-owned subsidiary EMS Wiring Systems Pte Ltd has received a USD200,000 grant from Enterprise Singapore to develop a prototype liquid film cooling system for use in data centres. The entire development is valued at approximately USD1 million and will take about 12-18 months to complete.

----------

Inspirit Energy Holdings PLC - developer of combined heat and power boilers - In talks regarding a possible collaboration with an engineering company with expertise in advanced gasification. The collaboration would enable Inspirit to support the heat recovery processes within this partner's applications, it says. "In particular, Inspirit may be afforded the opportunity to participate in district heating, waste-to-energy and other energy infrastructure projects using the partner's gasification technology," says Inspirit. Will update market when the parties enter into formal collaboration.

----------

Medica Group PLC - teleradiology services provider based in Hastings, East Sussex - To buy Global Diagnostics Ireland, operating in the teleradiology reporting market in Ireland, for an initial cash consideration of EUR16 million. The deal is in line with Medica's strategy to diversify revenue sources outside of the UK, to further its market leadership position in teleradiology and expand into new areas of telemedicine. A maximum of EUR4 million deferred consideration will be paid based on contractual milestones. Adds that recent Medica trading has been in line with management expectations.

----------

Biome Technologies PLC - bioplastics and radio frequency technology - Bioplastics division starts project to develop and test a new generation of biodegradable tree shelters made from the company's bioplastics. The project has been awarded funding of GBP58,843 from the government-backed Innovate UK agency. Tree shelters are used to protect young trees and bushes from animals. This three-month project is being undertaken in conjunction with Suregreen, a tree shelter manufacturer.

----------

Mila Resources PLC - natural resources company - Though transaction to buy E-Tech Metals Ltd was "materially advanced" following due diligence and the preparation of a prospectus, E-Tech gave notice that it wished to terminate the transaction without cause. Mila has now recovered a loan of GBP87,402 advanced to E-Tech, and is receiving legal advice on the termination notice. "Mila Resources maintains a healthy cash position and is in advanced discussions with regard to other potential transactions and will update the market in due course," says Mila. Adds that trading in its shares will resume in due course following consultation with the UK Financial Conduct Authority. A further statement will be made to "clarify lifting of the suspension".

----------

By Lucy Heming; lucyheming@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
22 Feb 2024 14:02

IN BRIEF: IQ-AI shares sink on discounted placing fundraise

IQ-AI Ltd - Medical services firm and parent company of Wisconsin-based healthcare imaging software firm Imaging Biometrics LLC - Announces placing to raise GBP300,000 gross proceeds via the issue of 20.0 million new shares at a price of 1.5p each. The issue price represents a discount of 32% to the company's Wednesday closing price of 2.2p. The placing includes a broker option for existing shareholders for up to 6.7 million new shares, which would raise an additional GBP100,000. Admission of the new placing and broker option shares is expected to occur on or around March 1.

Read more
9 Feb 2024 13:38

IQ-AI subsidiary asked by FDA to resubmit and modify application

(Alliance News) - IQ-AI Ltd on Friday said its subsidiary Imaging Biometric LLC will modify and resubmit its application to the US Food & Drug Administration.

Read more
2 Feb 2024 08:56

IN BRIEF: IQ-AI celebrates USD100,000 grant for subsidiary

IQ-AI Ltd - St Helier, Jersey-based medical services firm - Says that Imaging Biometrics LLC, a wholly-owned subsidiary of IQ-AI, has been given a USD100,000 grant by the Musella Foundation For Brain Tumor Research & Information Inc. Explains that the grant will help to support the launch of an intermediate group expanded access programme, which is focused on giving brain tumour patients access to oral gallium maltolate, outside of an ongoing Phase One clinical trial at the Medical College of Wisconsin. The grant will be used to facilitate the expanded access programme, including writing and submitting the study protocol, patient screening and on-boarding.

Read more
10 Jan 2024 11:48

IQ-AI falls after subsidiary notes launch of treatment access scheme

(Alliance News) - IQ-AI Ltd shares fell on Wednesday, after it said its subsidiary Imaging Biometrics LLC is launching an intermediate population cohort expanded access programme for oral gallium maltolate.

Read more
19 Dec 2023 17:00

IQ-AI firm gets US FDA fast-track status for oral gallium maltolate

(Alliance News) - IQ-AI Ltd on Tuesday said the US Food & Drug Administration has granted 'fast-track" designation for oral gallium maltolate, which is its subsidiary Imaging Biometrics LLC's therapeutic for the treatment of adult patients with relapsed or refractory glioblastoma.

Read more
5 Dec 2023 11:49

IQ-AI stock rises on positive interim results from glioblastoma trial

(Alliance News) - IQ-AI Ltd on Tuesday reported positive results from Phase 1 of an on-going study for its investigational monotherapy oral gallium maltolate.

Read more
8 Nov 2023 12:04

IQ-AI says Imaging Biometrics submits paediatric rare disease request

(Alliance News) - IQ-AI Ltd on Wednesday said its wholly-owned subsidiary Imaging Biometrics LLC has submitted a paediatric rare disease request to the US Food & Drug Administration for its gallium maltolate therapy.

Read more
18 Oct 2023 17:11

IN BRIEF: IQ-AI subsidiary "central" to "landmark" brain cancer study

IQ-AI Ltd - St Helier, Jersey-based medical services firm focused on cancer treatment - Notes its wholly-owned subsidiary, Imaging Biometrics LLC (IB), has announced the results of a "landmark" study. Says the study represents the first large-scale characterization of the invasive tumour margins of high-grade glioma using multi-regional genomic/transcriptomic sequencing with spatially matched MRI measurements in glioma. High-grade glioma is a deadly brain cancer. Explains that Imaging Biometrics' IB Neuro's dynamic susceptibility contrast magnetic resonance imaging software was central to the study.

Read more
9 Oct 2023 12:09

IN BRIEF: IQ-AI subsidiary wins orphan drug designation from US FDA

IQ-AI Ltd - St Helier, Jersey-based medical services firm focused on cancer treatment - Wholly-owned subsidiary Imaging Biometrics LLC is granted an orphan drug designation from the US Food & Drug Administration for gallium maltolate for the treatment of atypical teratoid rhabdoid tumour. Notes this is the second orphan designation granted to gallium maltolate this year.

Read more
8 Sep 2023 10:25

IQ-AI notes vindication of subsidiary's reduced gadolinium approach

(Alliance News) - IQ-AI Ltd on Friday noted that studies by its subsidiary Imaging Biometrics LLC validated the dosing approach of Imaging's MRI-focused IB Neuro.

Read more
18 Aug 2023 12:17

IQ-AI shares jump on subsidiary's GE Healthcare deal

(Alliance News) - IQ-AI Ltd on Friday said its wholly-owned subsidiary Imaging Biometrics LLC has signed a deal with GE HealthCare Technologies Inc.

Read more
17 Aug 2023 11:21

IQ-AI interim loss narrows amid higher revenue, lower expenses

(Alliance News) - IQ-AI Ltd on Thursday announced a slightly lower loss for the six months to June 30, as revenue was up and administrative expenses were lower.

Read more
19 Jul 2023 10:45

IN BRIEF: IQ-AI subsidiary's app adopted by US medical college

IQ-AI Ltd - Jersey-based medical services firm focused on cancer treatment - Says subsidiary Imaging Biometrics LLC's handheld application IB Nimble has been adopted by the Medical College of Wisconsin's Orthopedic Department for use in bone metastases treatment. IB Nimble's designer, Joseph Bovi, is professor of radiation oncology & neurosurgery at MCW. The application was originally designed to help treat brain metastases. IQ-AI says it "provides real-time collaboration amongst multi-disciplinary teams" to "provide optimised treatments faster". Josh McComack, Imaging Biometrics' director of software engineering, says the new installation "demonstrates that IB Nimble is ready for widespread deployment."

Read more
13 Jul 2023 11:36

IN BRIEF: IQ-AI granted orphan drug designation for Gallium Galtolate

IQ-AI Ltd on Thursday - Jersey-based incubator of software and other tools for the treatment of cancer - IQ-AI subsidiary Imaging Biometrics LLC has been granted an orphan drug designation for Gallium Galtolate for the treatment of paediatric glioblastoma multiforme, or GBM, by the US Food & Drug Administration. Says GBM is the most common and aggressive primary brain tumour in adults and children. Imaging Biometrics' application to the FDA was first submitted in April. In June, two pre-clinical studies showed oral GaM inhibits brain tumour growth in children, and the results were consistent with previous work conducted in the Schmainda Lab at the Medical College of Wisconsin.

Read more
27 Jun 2023 11:47

IN BRIEF: IQ-AI notes Gallium Moltate studies on tumour growth

IQ-AI Ltd - Jersey-based medical services firm - Says subsidiary Imaging Biometrics LLC's two new pre-clinical studies show oral Gallium Maltolate inhibits brain tumour growth in children. Says the results are consistent with previous work conducted in the Schmainda Lab at the Medical College of Wisconsin. This follows IB's application for Orphan Drug Designation to the US Food & Drug Administration back in April for the use of GaM in pediatric brain tumours. Notes application is currently under review.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.